Codexis, Inc. Stock price

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
3.51 USD +1.74% Intraday chart for Codexis, Inc. +0.57% +15.08%
Sales 2024 * 65.38M Sales 2025 * 62.05M Capitalization 247M
Net income 2024 * -46M Net income 2025 * -49M EV / Sales 2024 * 3.77 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.98 x
P/E ratio 2024 *
-5.44 x
P/E ratio 2025 *
-5.14 x
Employees 174
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.74%
1 week+0.57%
Current month-24.52%
1 month-15.42%
3 months+4.15%
6 months+126.45%
Current year+15.08%
More quotes
1 week
3.40
Extreme 3.4
3.59
1 month
3.04
Extreme 3.035
4.91
Current year
2.53
Extreme 2.53
4.91
1 year
1.45
Extreme 1.45
4.91
3 years
1.45
Extreme 1.45
42.01
5 years
1.45
Extreme 1.45
42.01
10 years
1.34
Extreme 1.34
42.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 20-06-15
Director of Finance/CFO 43 23-01-22
Compliance Officer 53 22-10-31
Members of the board TitleAgeSince
Director/Board Member 64 16-02-29
Director/Board Member 59 22-09-27
Chief Executive Officer 64 20-06-15
More insiders
Date Price Change Volume
24-03-27 3.51 +1.74% 497,241
24-03-26 3.45 0.00% 337,252
24-03-25 3.45 0.00% 350,116
24-03-22 3.45 -1.15% 331,753
24-03-21 3.49 0.00% 423,968

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and selling enzymes and other proteins. The Company commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.51 USD
Average target price
6.571 USD
Spread / Average Target
+87.22%
Consensus
  1. Stock
  2. Equities
  3. Stock Codexis, Inc. - Nasdaq